An interventional study of A Novel Two-Tooth Endoscopic Clip and Clip in GIST - Gastrointestinal Stromal Tumor, sponsored by Affiliated Hospital to Academy of Military Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Affiliated Hospital to Academy of Military Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Gastrointestinal Stromal Tumors with a site in China — 24 open to participants now, 28 under way, 4 of them phase 3. Gastrointestinal Stromal Tumors · China.
Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, this one is the 33rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2026, is one of 16 with no phase, reaches primary completion later than 15 of the 27 other live ones, and was the 67th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →24 of the 69 studies in Gastrointestinal Stromal Tumors with a site in China are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in China, United States, Argentina and 17 more countries
Ages 18+
Ningbo Newbay Technology Development Co., Ltd · Sites in China, Korea, Republic of
Ages 18+
GlaxoSmithKline · Sites in China, United States, Australia and 16 more countries
Ages 18+
Huazhong University of Science and Technology · Sites in China
Ages 18+
Jian Li · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 9 · Phase 4 2
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 100 across the 46 interventional studies, 181 across the 22 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 69 have an industry lead sponsor. The 10 most frequent:
Affiliated Hospital to Academy of Military Medical Sciences is the lead sponsor of 67 studies on the registry; 10 are open to participants now.
Affiliated Hospital to Academy of Military Medical Sciences has 1 study filed under Gastrointestinal Stromal Tumors — fewer than ten, so there is no comparison to draw.
7 of the studies in Gastrointestinal Stromal Tumors with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05245968Taiho Pharmaceutical Co., Ltd.A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | 2026-12 |
| NCT05489237IDRX, Inc., a wholly owned subsidiary of GSK, LLCFirst-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | 2027-03-10 |
| NCT06926374Chinese University of Hong KongProspective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | 2027-04 |
| NCT07581977Affiliated Hospital to Academy of Military Medical SciencesA Novel Two-Tooth Clip for ESD and EFTR of GIST | 2027-04-24 |
| NCT07559864Jian LiComparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the efficacy and safety of a novel two-tooth endoscopic clip, utilized in a "clip with line" traction configuration, during endoscopic resection procedures (ESD and EFTR) of GIST. The novel clip's dual-tooth design is intended to provide a more secure anchor on the lesion, enabling effective counter-traction when combined with a line. The primary aim is to determine if this method improves submucosal dissection efficiency compared to conventional ESD. A secondary aim is to evaluate the performance of the same clip system for full-thickness or mucosal defect closure.
Endoscopic Submucosal Dissection (ESD) and Endoscopic Full-Thickness Resection (EFTR) are established, minimally invasive techniques for the en-bloc resection of gastrointestinal stromal tumor (GIST). However, a persistent challenge, especially in difficult locations or large lesions, is the lack of sufficient counter-traction, which leads to prolonged procedure times, increased risk of intraoperative bleeding, and potential for incomplete resection due to poor visualization of the submucosal layer. Furthermore, managing large post resection defects or perforations requires reliable and technically feasible endoscopic suturing.
This study introduces a novel two-tooth clip. The device's geometry is hypothesized to provide a stronger, more stable grasp on the targeted tissue compared to standard single-tooth or non-toothed clips. The study will investigate two sequential applications of this clip within a single procedure:
The Traction Phase: A "clip with line" technique will be employed. The novel two-tooth clip will be anchored to the proximal edge of the lesion. A dental line, pre-tied to the clip, will be used by the endoscopist to apply adjustable counter-traction. This is intended to lift the lesion, tauten the submucosal fibers, and clearly expose the dissection plane, thereby simulating the principle of surgical counter-traction.
The Closure Phase: Following lesion resection, the novel two-tooth clip will be utilized to perform a continuous, circumferential closure of the mucosal defect or perforation. The study will assess the technical success rate, time required for complete closure, and the clip's ability to securely approximate tissue layers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo ESD or EFTR using the "clip with line" traction method with the novel two-tooth clip. After initial circumferential mucosal incision, the two-tooth clip (with pre-tied line) will be anchored to the lesion. The endoscopist will apply continuous or intermittent traction via the line to optimize the submucosal view. After lesion retrieval, defects requiring closure will be managed using the same novel two-tooth clips in a purse-string configuration.
Device: A Novel Two-Tooth Endoscopic Clip
Patients will undergo standard ESD or EFTR without the use of dedicated traction devices. The endoscopist may use transparent cap assistance and positional changes for exposure, which is current standard practice.
Device: Clip
"Clip with line" traction method with the novel two-tooth clip will be applied in patients undergoing ESD or EFTR. After lesion retrieval, defects requiring closure will be managed using the same novel two-tooth clips.
Standard ESD or EFTR without the use of dedicated traction devices will be performed, then using the standard clips for closure.
Submucosal Dissection Efficiency
The rate of submucosal dissection (measured in mm²/min), calculated from the start of submucosal entry to the completion of lesion removal.
Time frame: 24 hours
Technical Success Rate of Purse-String Closure
Percentage of cases where complete, circumferential mucosal/full-thickness defect closure is achieved using the novel two-tooth clip without conversion to alternative closure devices.
Time frame: 24 hours
Incidence of Intraoperative Adverse Events
* Rates of immediate perforation (unintended) in both groups during the dissection phase * Rates of significant active bleeding requiring emergency hemostasis (aside from planned vessel coagulation) in both groups during the dissection phase * Rates of muscularis injury in both groups during the dissection phase
Time frame: 3 days
Defect Closure Time
Time taken to achieve complete purse-string closure of the post-resection defect.
Time frame: 24 hours
Post-procedural Outcomes
* Rates of delayed bleeding within 90 days * Rates of delayed perforation within 90 days * Rates of post-polypectomy electrocoagulation syndrome within 90 days
Time frame: 3 months
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gastrointestinal Stromal Tumors →
Affiliated Hospital to Academy of Military Medical Sciences